Genetic markers associated with length of abstinence in acamprosate treatment

Publisher： John Wiley & Sons Inc

E-ISSN： 1556-7532|26|4|4-5

ISSN： 1068-5308

Source： THE BROWN UNIVERSITY PSYCHOPHARMACOLOGY UPDATE, Vol.26, Iss.4, 2015-04, pp. : 4-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness of Adjuvant Treatment with Acamprosate in Maintaining Abstinence in Alcohol Dependent Patients

By  

European Addiction Research, Vol. 9, Iss. 2, 2003-03 ,pp. : 59-64

Karger

Access to resources Recommend Favorite

Home‐based detoxification for neonatal abstinence syndrome reduces length of hospital admission without prolonging treatment

By  

ACTA PAEDIATRICA, Vol. 103, Iss. 6, 2014-06 ,pp. : 601-604

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic Evaluation of Campral® (Acamprosate) Compared to Placebo in Maintaining Abstinence in Alcohol-Dependent Patients

By  

European Addiction Research, Vol. 6, Iss. 2, 2000-07 ,pp. : 71-78

Karger

Access to resources Recommend Favorite

An Open Study with Acamprosate in Belgium and Luxemburg: Results on Sociodemographics, Supportive Treatment and Outcome

By  

European Addiction Research, Vol. 6, Iss. 3, 2000-11 ,pp. : 132-140

Karger

Access to resources Recommend Favorite

Murphy opioid treatment hearing: Abstinence and Vivitrol

By  

ALCOHOLISM AND DRUG ABUSE WEEKLY, Vol. 27, Iss. 18, 2015-05 ,pp. : 5-7

John Wiley & Sons Inc

Access to resources Recommend Favorite